The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review
Abstract Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important...
Gespeichert in:
| Veröffentlicht in: | European neuropsychopharmacology 2010-02, Vol.20 (2), p.69-79 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | 2 |
| container_start_page | 69 |
| container_title | European neuropsychopharmacology |
| container_volume | 20 |
| creator | Crunelle, Cleo L Miller, Michelle L Booij, Jan van den Brink, Wim |
| description | Abstract Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an α4β2 nAChR partial agonist and an α7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence. |
| doi_str_mv | 10.1016/j.euroneuro.2009.11.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733930250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X09002521</els_id><sourcerecordid>733930250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-5b8332c3dfc44d5afc91c39511027dcb518a27f451ad96c6ee5109a6c8ad87133</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEokvhFcAnekrw2HESc0BaVdAiVeJAkbhZXnvSesnai-0U7dvjsCuQOCAu48s3_0jf76p6BbQBCt2bbYNzDH4ZDaNUNgANpfCoWsHQ87ofOva4WlHJ2lr2_dez6llK2wIIzuXT6gykFJK3dFWF23sk3pmQXZlEG8yHydyHyXkkEQ3uc4hkr2N2eiL6LniXMnnQEQv-C9LeklxCckSdd-gzCSOxcb4jFvfoLXqDb8m6hD04_PG8ejLqKeGL03teffnw_vbyur75dPXxcn1Tm1Z0uRabgXNmuB1N21qhRyPBcCkAKOut2QgYNOvHVoC2sjMdogAqdWcGbYceOD-vLo65-xi-z5iy2rlkcJq0xzAn1RcRnDJBC_n6nyQDNgxMLmB_BE0MKUUc1T66nY4HBVQtrait-t2KWlpRAKpIL5svTyfmzQ7tn71TDQVYHwEsSoqmqJJxizjrSgdZ2eD-48i7vzKWfpzR0zc8YNqGOfpiXIFKTFH1efkcy9-gkhYPDPhPANu5bw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21288290</pqid></control><display><type>article</type><title>The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Crunelle, Cleo L ; Miller, Michelle L ; Booij, Jan ; van den Brink, Wim</creator><creatorcontrib>Crunelle, Cleo L ; Miller, Michelle L ; Booij, Jan ; van den Brink, Wim</creatorcontrib><description>Abstract Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an α4β2 nAChR partial agonist and an α7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2009.11.001</identifier><identifier>PMID: 19959340</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Addiction ; Alcohol Drinking - drug therapy ; Alpha4 beta2 nicotinic acetylcholine receptor ; Animals ; Behavior, Addictive - drug therapy ; Benzazepines - pharmacology ; Benzazepines - therapeutic use ; Brain - drug effects ; Brain - physiopathology ; Dopamine - physiology ; Drug dependence ; Drug Partial Agonism ; Humans ; Internal Medicine ; Neurotransmitter Agents - physiology ; Nicotinic Agonists - therapeutic use ; Partial agonist ; Psychiatry ; Quinoxalines - pharmacology ; Quinoxalines - therapeutic use ; Receptors, Nicotinic - drug effects ; Receptors, Nicotinic - physiology ; Relapse prevention ; Secondary Prevention ; Smoking Cessation ; Substance-Related Disorders - drug therapy ; Substance-Related Disorders - physiopathology ; Substance-Related Disorders - prevention & control ; Varenicline</subject><ispartof>European neuropsychopharmacology, 2010-02, Vol.20 (2), p.69-79</ispartof><rights>Elsevier B.V. and ECNP</rights><rights>2009 Elsevier B.V. and ECNP</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-5b8332c3dfc44d5afc91c39511027dcb518a27f451ad96c6ee5109a6c8ad87133</citedby><cites>FETCH-LOGICAL-c456t-5b8332c3dfc44d5afc91c39511027dcb518a27f451ad96c6ee5109a6c8ad87133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924977X09002521$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19959340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crunelle, Cleo L</creatorcontrib><creatorcontrib>Miller, Michelle L</creatorcontrib><creatorcontrib>Booij, Jan</creatorcontrib><creatorcontrib>van den Brink, Wim</creatorcontrib><title>The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>Abstract Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an α4β2 nAChR partial agonist and an α7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.</description><subject>Addiction</subject><subject>Alcohol Drinking - drug therapy</subject><subject>Alpha4 beta2 nicotinic acetylcholine receptor</subject><subject>Animals</subject><subject>Behavior, Addictive - drug therapy</subject><subject>Benzazepines - pharmacology</subject><subject>Benzazepines - therapeutic use</subject><subject>Brain - drug effects</subject><subject>Brain - physiopathology</subject><subject>Dopamine - physiology</subject><subject>Drug dependence</subject><subject>Drug Partial Agonism</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Neurotransmitter Agents - physiology</subject><subject>Nicotinic Agonists - therapeutic use</subject><subject>Partial agonist</subject><subject>Psychiatry</subject><subject>Quinoxalines - pharmacology</subject><subject>Quinoxalines - therapeutic use</subject><subject>Receptors, Nicotinic - drug effects</subject><subject>Receptors, Nicotinic - physiology</subject><subject>Relapse prevention</subject><subject>Secondary Prevention</subject><subject>Smoking Cessation</subject><subject>Substance-Related Disorders - drug therapy</subject><subject>Substance-Related Disorders - physiopathology</subject><subject>Substance-Related Disorders - prevention & control</subject><subject>Varenicline</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNksFu1DAQhiMEokvhFcAnekrw2HESc0BaVdAiVeJAkbhZXnvSesnai-0U7dvjsCuQOCAu48s3_0jf76p6BbQBCt2bbYNzDH4ZDaNUNgANpfCoWsHQ87ofOva4WlHJ2lr2_dez6llK2wIIzuXT6gykFJK3dFWF23sk3pmQXZlEG8yHydyHyXkkEQ3uc4hkr2N2eiL6LniXMnnQEQv-C9LeklxCckSdd-gzCSOxcb4jFvfoLXqDb8m6hD04_PG8ejLqKeGL03teffnw_vbyur75dPXxcn1Tm1Z0uRabgXNmuB1N21qhRyPBcCkAKOut2QgYNOvHVoC2sjMdogAqdWcGbYceOD-vLo65-xi-z5iy2rlkcJq0xzAn1RcRnDJBC_n6nyQDNgxMLmB_BE0MKUUc1T66nY4HBVQtrait-t2KWlpRAKpIL5svTyfmzQ7tn71TDQVYHwEsSoqmqJJxizjrSgdZ2eD-48i7vzKWfpzR0zc8YNqGOfpiXIFKTFH1efkcy9-gkhYPDPhPANu5bw</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Crunelle, Cleo L</creator><creator>Miller, Michelle L</creator><creator>Booij, Jan</creator><creator>van den Brink, Wim</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20100201</creationdate><title>The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review</title><author>Crunelle, Cleo L ; Miller, Michelle L ; Booij, Jan ; van den Brink, Wim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-5b8332c3dfc44d5afc91c39511027dcb518a27f451ad96c6ee5109a6c8ad87133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Addiction</topic><topic>Alcohol Drinking - drug therapy</topic><topic>Alpha4 beta2 nicotinic acetylcholine receptor</topic><topic>Animals</topic><topic>Behavior, Addictive - drug therapy</topic><topic>Benzazepines - pharmacology</topic><topic>Benzazepines - therapeutic use</topic><topic>Brain - drug effects</topic><topic>Brain - physiopathology</topic><topic>Dopamine - physiology</topic><topic>Drug dependence</topic><topic>Drug Partial Agonism</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Neurotransmitter Agents - physiology</topic><topic>Nicotinic Agonists - therapeutic use</topic><topic>Partial agonist</topic><topic>Psychiatry</topic><topic>Quinoxalines - pharmacology</topic><topic>Quinoxalines - therapeutic use</topic><topic>Receptors, Nicotinic - drug effects</topic><topic>Receptors, Nicotinic - physiology</topic><topic>Relapse prevention</topic><topic>Secondary Prevention</topic><topic>Smoking Cessation</topic><topic>Substance-Related Disorders - drug therapy</topic><topic>Substance-Related Disorders - physiopathology</topic><topic>Substance-Related Disorders - prevention & control</topic><topic>Varenicline</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crunelle, Cleo L</creatorcontrib><creatorcontrib>Miller, Michelle L</creatorcontrib><creatorcontrib>Booij, Jan</creatorcontrib><creatorcontrib>van den Brink, Wim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crunelle, Cleo L</au><au>Miller, Michelle L</au><au>Booij, Jan</au><au>van den Brink, Wim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>20</volume><issue>2</issue><spage>69</spage><epage>79</epage><pages>69-79</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>Abstract Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an α4β2 nAChR partial agonist and an α7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19959340</pmid><doi>10.1016/j.euroneuro.2009.11.001</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-977X |
| ispartof | European neuropsychopharmacology, 2010-02, Vol.20 (2), p.69-79 |
| issn | 0924-977X 1873-7862 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733930250 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Addiction Alcohol Drinking - drug therapy Alpha4 beta2 nicotinic acetylcholine receptor Animals Behavior, Addictive - drug therapy Benzazepines - pharmacology Benzazepines - therapeutic use Brain - drug effects Brain - physiopathology Dopamine - physiology Drug dependence Drug Partial Agonism Humans Internal Medicine Neurotransmitter Agents - physiology Nicotinic Agonists - therapeutic use Partial agonist Psychiatry Quinoxalines - pharmacology Quinoxalines - therapeutic use Receptors, Nicotinic - drug effects Receptors, Nicotinic - physiology Relapse prevention Secondary Prevention Smoking Cessation Substance-Related Disorders - drug therapy Substance-Related Disorders - physiopathology Substance-Related Disorders - prevention & control Varenicline |
| title | The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T19%3A00%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20nicotinic%20acetylcholine%20receptor%20partial%20agonist%20varenicline%20and%20the%20treatment%20of%20drug%20dependence:%20A%20review&rft.jtitle=European%20neuropsychopharmacology&rft.au=Crunelle,%20Cleo%20L&rft.date=2010-02-01&rft.volume=20&rft.issue=2&rft.spage=69&rft.epage=79&rft.pages=69-79&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2009.11.001&rft_dat=%3Cproquest_cross%3E733930250%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21288290&rft_id=info:pmid/19959340&rft_els_id=S0924977X09002521&rfr_iscdi=true |